BMO Capital raises Oracle stock price target to $345 on strong bookings

Published 10/09/2025, 14:52
BMO Capital raises Oracle stock price target to $345 on strong bookings

Investing.com - BMO Capital has raised its price target on Oracle (NYSE:ORCL) to $345.00 from $275.00 while maintaining an Outperform rating on the stock. The tech giant, currently valued at over $950 billion, has seen its shares surge more than 8% in the past week, though InvestingPro analysis suggests the stock is trading above its Fair Value.

The research firm cited Oracle’s "incredibly strong bookings quarters," which was reflected in the company’s 359% year-over-year RPO (Remaining Performance Obligation) growth, prompting BMO to raise its long-term forecast for the company.

BMO Capital noted that despite what it called a "lackluster" August quarter and November quarter revenue guidance, Oracle management is guiding for mid-teens fiscal year 2026 operating income growth.

The firm expressed "incremental confidence in the durability of Oracle’s revenue and operating income growth" based on these factors.

BMO Capital expects more details on Oracle’s longer-term financial model, including financing information, to be revealed at the company’s October Analyst event.

In other recent news, Oracle has reported impressive first-quarter results, showcasing accelerating top-line growth and record sales performance across several key metrics, including Cloud Revenue and multi-cloud database revenue. Analysts have taken note of these developments, with Guggenheim raising its price target for Oracle to $375, citing strong cloud performance and a promising outlook in the software sector. Piper Sandler also increased its price target to $330, highlighting Oracle’s transformation into a leader in AI infrastructure.

Additionally, Oracle has launched an AI Center of Excellence for Healthcare, aiming to assist healthcare organizations in implementing AI solutions. The company plans to enhance its Health Patient Portal by integrating AI capabilities, allowing patients to receive explanations of their medical records through OpenAI’s technology, with a general availability expected in 2026. Despite these advancements, Oppenheimer maintained a Perform rating for Oracle, acknowledging impressive results but expressing concerns about capital expenditures. These developments reflect Oracle’s ongoing efforts to expand its AI and cloud capabilities.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.